ADVERTISEMENT
Posted: May 7, 2025

Recognizing benzodiazepine-induced neurological dysfunction

CPE

An estimated 30.6 million adults in the United States will use benzodiazepines within the past year. Benzodiazepines are prescribed for a wide range of conditions, including anxiety, insomnia, muscle spasms, anesthesia, catatonia, status epilepticus, and withdrawal from alcohol or benzodiazepines.

Thao Anh Mai, PharmD; Kami Johnston, PharmD; Jeffrey D. Gold, PharmD, BCPP

Read more
Posted: Apr 7, 2025

New guidelines for clinical management of acne

CPE

Acne vulgaris is a prevalent dermatological condition that significantly affects individuals’ quality of life and poses substantial challenges in clinical management.

Jamie L. McConaha, PharmD, NCTTP, BCACP, CDCES; Lucia Massaro, PharmD Candidate 2025; Morgan Newton, PharmD Candidate 2025

Read more
Posted: Mar 7, 2025

Cybersecurity and HIPAA compliance: Essentials for pharmacists

CPE

In February 2024, one of the largest data breaches recorded affected Change Healthcare, a data processing entity of UnitedHealth Group.

Shawn Bookwalter, PharmD, MSHI, MS, BCPS, FISMP, Deputy Director, Immunization Healthcare Division, Defense Health Agency, Falls Church, VA

Read more
Posted: Feb 7, 2025

New therapeutic agents marketed in 2024: Part 1

CPE

FDA approved 50 new (“novel”) drugs in 2024 that had not been approved or marketed in the United States.

Mark S. Johnson, PharmD, BCPS

Read more
Posted: Jan 7, 2025

Advancing diabetes care: Highlights from the 2025 guidelines update

CPE

In December 2024, the American Diabetes Association (ADA) published the newest Standards of Care in Diabetes for the upcoming year.

Michelle Dano, PharmD

Read more
1345678910Last

Related Articles

Advertisement
Advertisement
Advertisement
Advertisement
ADVERTISEMENT